# GLP-1 Cost and Insurance Coverage: How to Actually Get These Drugs Covered

Source: https://www.dietglp.com/blog/glp1-cost-and-coverage/
Published: 2026-03-27
Keywords: ozempic insurance cost, wegovy coverage, mounjaro price, glp-1 prior authorization

**TL;DR:** List prices for GLP-1 medications run $900–1,400/month. Insurance often requires prior authorization (BMI documentation, comorbidities, prior weight-loss attempts). Manufacturer direct-pay programs (LillyDirect, NovoCare) offer cash prices around $500–650/month. Check savings cards. Switching to a covered alternative is sometimes the answer.

If you've tried to fill a Wegovy or Zepbound prescription and seen a $1,400 sticker, you're not alone. The list prices are extraordinary. The actual costs you pay depend on insurance, savings programs, manufacturer cash-pay options, and a fair amount of administrative effort.

## List prices (April 2026)

Approximate U.S. list prices per month:

- **Wegovy** (semaglutide for weight): ~$1,350
- **Ozempic** (semaglutide for diabetes): ~$1,000
- **Zepbound** (tirzepatide for weight): ~$1,060
- **Mounjaro** (tirzepatide for diabetes): ~$1,070
- **Saxenda** (liraglutide for weight): ~$1,400
- **Victoza** (liraglutide for diabetes): ~$815

These are list prices. Almost no one pays them in full.

## Insurance coverage — diabetes vs weight loss

Coverage usually splits along the FDA-approved indication:

**Diabetes (Ozempic, Mounjaro, Victoza):**
- Often covered by most insurance for type 2 diabetes
- Step therapy may apply (try metformin first)
- Some plans require prior auth even for diabetes

**Weight management (Wegovy, Zepbound, Saxenda):**
- Covered by some insurance, not most
- Usually requires BMI ≥30 (or ≥27 with comorbidity)
- Prior authorization is the rule
- Documentation of prior weight loss attempts often required
- Periodic re-authorization (12-month renewals)

**Medicare:**
- Does NOT currently cover GLP-1 specifically for weight loss (this may change)
- Covers Ozempic and Mounjaro for diabetes
- Covers Wegovy specifically for cardiovascular event reduction in patients with established CVD (a 2024 expansion)

**Medicaid:**
- Coverage varies wildly by state
- Many state Medicaid programs do not cover weight-loss indications
- Better coverage for diabetes indications

## Manufacturer direct-pay programs

If your insurance won't cover, the manufacturer cash-pay programs are usually your best bet:

**LillyDirect** (Zepbound, Mounjaro):
- Self-pay program with significant discounts
- Zepbound vials (single-dose): ~$400–500/month at lower doses
- Direct shipping
- Eligible without insurance approval

**NovoCare** (Wegovy):
- Similar self-pay program
- Various dose-strength savings
- Roughly $500–650/month for self-pay
- For current Wegovy pill prices by dose, the subscription plans and the Medicare GLP-1 Bridge, see our [Wegovy pill cost guide](/blog/wegovy-pill-cost/)

**Savings cards** (for insured patients):
- Manufacturer cards can reduce copays significantly
- Wegovy savings card can bring copays to as low as $0–25/month for eligible patients with commercial insurance
- Mounjaro/Zepbound savings card similar
- Eligibility usually excludes Medicare/Medicaid patients

## Strategies to get coverage

If your insurance denies:

**1. Appeal.** Many denials are reversed on appeal with proper documentation. Your prescriber's office should help.

**2. Document comorbidities.** Type 2 diabetes, sleep apnea, hypertension, hyperlipidemia, fatty liver — these support medical necessity.

**3. Document prior attempts.** Weight Watchers, Noom, prior medications, behavioral programs. Show that lifestyle alone hasn't worked.

**4. Switch indication products.** If you have type 2 diabetes alongside obesity, Ozempic or Mounjaro may be covered while Wegovy or Zepbound isn't.

**5. Try a less-restricted alternative.** Saxenda is sometimes covered when Wegovy isn't.

**6. Ask about pharmacy benefit alternatives.** Some plans have specialty pharmacies with different formularies.

**7. Use a patient assistance program.** Both Lilly and Novo Nordisk have programs for low-income patients.

## What about compounded?

Compounded semaglutide and tirzepatide were widely available and inexpensive ($150–400/month) during the FDA shortage period (2023–2024). As supplies have stabilized, the FDA has restricted compounding.

Risks (covered in detail in our compounded GLP-1 guide):
- Variable purity
- Counterfeits in the gray market
- No standardized FDA review

If brand-name is unaffordable and compounded is your only option, vet the pharmacy carefully.

## What about international/online?

Some patients import medication from Canada, Mexico, or other countries. Legal status varies. Personal-use importation has historically been tolerated but exists in a gray area. Quality varies. Caution warranted.

Telehealth pharmacy services proliferated in 2023–2024. Some are legitimate; some prescribe with minimal oversight. Look for ones with real medical evaluation, not "fill out a form, get a script."

## Cost comparison summary

For a typical patient targeting effective weight loss:

- **Best case:** Insurance covers, copay $25–100/month
- **Mid case:** Manufacturer cash pay, $400–650/month
- **High case:** Out-of-pocket retail, $1,000–1,400/month
- **Compounded (with caveats):** $200–500/month
- **No medication (lifestyle only):** $0 + likely much smaller weight loss

## When to push, when to accept

Push hard for coverage if:
- You have a labeled indication and insurance is being inflexible
- You have multiple comorbidities
- Your prescriber strongly supports the medication

Accept and pivot if:
- Multiple appeals have failed
- Cash-pay through manufacturer is workable for your budget
- A different drug is covered that may also work for you
- You're a candidate for less-aggressive intervention (lifestyle + a non-GLP-1 weight medication)

## What's coming

Several things may change the cost landscape:

- **Generic semaglutide** could enter the market starting around 2026 (varies by jurisdiction)
- **Generic liraglutide** is expected to be more widely available
- **Negotiated Medicare prices** under the Inflation Reduction Act may include some GLP-1s
- **More commercial competition** as new triple agonists arrive

The cost picture in 2027 may look meaningfully different from today.

## Bottom line

GLP-1 medications are expensive but increasingly accessible. Insurance coverage is the first option (BMI documentation, prior auth, appeals if denied). Manufacturer direct-pay programs are the second option (LillyDirect, NovoCare). Savings cards help insured patients with high copays. Compounded is a last-resort option with real safety caveats. Don't assume the sticker price is what you'll pay — work the system.